| Nature Reviews Drug Discovery | |
| Cover: | Nature Review Drug Discovery.jpg |
| Abbreviation: | Nat. Rev. Drug Discov. |
| Discipline: | Pharmacology, Biotechnology |
| Editor: | Peter Kirkpatrick |
| Publisher: | Nature Portfolio |
| History: | 2002–present |
| Frequency: | Monthly |
| Impact: | 120.1 |
| Impact-Year: | 2022 |
| Issn: | 1474-1776 |
| Eissn: | 1474-1784 |
| Coden: | NRDDAG |
| Lccn: | 2002243044 |
| Oclc: | 427380493 |
| Website: | http://www.nature.com/nrd/ |
| Link1: | http://www.nature.com/nrd/current_issue |
| Link1-Name: | Online access |
| Link2: | http://www.nature.com/nrd/volumes/ |
| Link2-Name: | Online archive |
Nature Reviews Drug Discovery is a monthly peer-reviewed review journal published by Nature Portfolio. It was established in 2002[1] and covers drug discovery and development. The editor-in-chief is Peter Kirkpatrick.[2] According to the Journal Citation Reports, the journal has a 2021 impact factor of 112.288, ranking it 1st out of 158 journals in the category "Biotechnology & Applied Microbiology"[3] and 1st out of 279 journals in the category "Pharmacology & Pharmacy".[4]
Reviews are commissioned to specialists and supplemented with glossary explanations for non-specialist readers and illustrated with figures drawn by Nature's in-house art editors. Besides reviews, the journal publishes analysis articles based on existing datasets (e.g. metaanalysis), progress articles that focus on outstanding issues, and perspective articles - typically opinions or historical pieces.[5]